Teoxane sa announces superior proposal to acquire revance therapeutics for $3.60 per share in cash

Compelling cash proposal provides 16% premium over revance's amended and restated agreement with crown laboratories geneva , jan. 6, 2025 /prnewswire/ -- teoxane sa today announced that on january 6, 2025, it submitted a proposal to the board of directors of revance therapeutics, inc. (nasdaq: rvnc) to acquire revance for $3.60 per share in cash. teoxane beneficially owns 6.2% of the outstanding shares of common stock of revance.
RVNC Ratings Summary
RVNC Quant Ranking